325 related articles for article (PubMed ID: 34612690)
1. Population Pharmacokinetics and Dosing Optimization of Vancomycin in Pediatric Liver Transplant Recipients.
Shoji K; Saito J; Nakagawa H; Funaki T; Fukuda A; Sakamoto S; Kasahara M; Momper JD; Capparelli EV; Miyairi I
Microbiol Spectr; 2021 Oct; 9(2):e0046021. PubMed ID: 34612690
[TBL] [Abstract][Full Text] [Related]
2. Vancomycin pharmacokinetics and predicted dosage requirements in pediatric cancer patients.
Abdel Hadi O; Al Omar S; Nazer LH; Mubarak S; Le J
J Oncol Pharm Pract; 2016 Jun; 22(3):448-53. PubMed ID: 26079639
[TBL] [Abstract][Full Text] [Related]
3. Population pharmacokinetic analysis of vancomycin in pediatric continuous renal replacement therapy.
Moffett BS; Morris J; Munoz F; Arikan AA
Eur J Clin Pharmacol; 2019 Aug; 75(8):1089-1097. PubMed ID: 30937470
[TBL] [Abstract][Full Text] [Related]
4. Vancomycin dosing assessment in intensive care unit patients based on a population pharmacokinetic/pharmacodynamic simulation.
Revilla N; Martín-Suárez A; Pérez MP; González FM; Fernández de Gatta Mdel M
Br J Clin Pharmacol; 2010 Aug; 70(2):201-12. PubMed ID: 20653673
[TBL] [Abstract][Full Text] [Related]
5. Current recommended dosing of vancomycin for children with invasive methicillin-resistant Staphylococcus aureus infections is inadequate.
Frymoyer A; Hersh AL; Benet LZ; Guglielmo BJ
Pediatr Infect Dis J; 2009 May; 28(5):398-402. PubMed ID: 19295465
[TBL] [Abstract][Full Text] [Related]
6. Improved vancomycin dosing in children using area under the curve exposure.
Le J; Bradley JS; Murray W; Romanowski GL; Tran TT; Nguyen N; Cho S; Natale S; Bui I; Tran TM; Capparelli EV
Pediatr Infect Dis J; 2013 Apr; 32(4):e155-63. PubMed ID: 23340565
[TBL] [Abstract][Full Text] [Related]
7. Prediction of vancomycin pharmacodynamics in children with invasive methicillin-resistant Staphylococcus aureus infections: a Monte Carlo simulation.
Frymoyer A; Hersh AL; Coralic Z; Benet LZ; Joseph Guglielmo B
Clin Ther; 2010 Mar; 32(3):534-42. PubMed ID: 20399990
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of clinical outcome in children and adolescents receiving vancomycin for invasive infections due to methicillin-resistant Staphylococcus aureus: impact of increasing vancomycin MICs.
Arun A; Swamy S; Jacob K; Sharma R; Kohlhoff SA; Hammerschlag MR
Minerva Pediatr; 2018 Jun; 70(3):207-211. PubMed ID: 28006894
[TBL] [Abstract][Full Text] [Related]
9. Vancomycin population pharmacokinetics and dosing recommendations in haematologic malignancy with augmented renal clearance children.
Lv CL; Lu JJ; Chen M; Zhang R; Li QC; Chen YY; Liu TT
J Clin Pharm Ther; 2020 Dec; 45(6):1278-1287. PubMed ID: 32557716
[TBL] [Abstract][Full Text] [Related]
10. A Population Pharmacokinetics Model for Vancomycin Dosage Optimization Based on Serum Cystatin C.
Lu JJ; Chen M; Lv CL; Zhang R; Lu H; Cheng DH; Tang SY; Liu TT
Eur J Drug Metab Pharmacokinet; 2020 Aug; 45(4):535-546. PubMed ID: 32304024
[TBL] [Abstract][Full Text] [Related]
11. Population Pharmacokinetics and Dose Optimization of Vancomycin in Critically Ill Children.
Sridharan K; Abbasi MY; Mulubwa M
Eur J Drug Metab Pharmacokinet; 2021 Jul; 46(4):539-546. PubMed ID: 34156647
[TBL] [Abstract][Full Text] [Related]
12. Influence of venovenous extracorporeal membrane oxygenation on pharmacokinetics of vancomycin in lung transplant recipients.
Liu D; Chen W; Wang Q; Li M; Zhang Z; Cui G; Li P; Zhang X; Ma Y; Zhan Q; Wang C
J Clin Pharm Ther; 2020 Oct; 45(5):1066-1075. PubMed ID: 32542736
[TBL] [Abstract][Full Text] [Related]
13. Vancomycin dosage optimization in patients with malignant haematological disease by pharmacokinetic/pharmacodynamic analysis.
Fernández de Gatta Mdel M; Santos Buelga D; Sánchez Navarro A; Dominguez-Gil A; García MJ
Clin Pharmacokinet; 2009; 48(4):273-80. PubMed ID: 19492872
[TBL] [Abstract][Full Text] [Related]
14. Determination of vancomycin exposure target and individualised dosing recommendations for neonates: model-informed precision dosing.
Tang Z; Guan J; Li J; Yu Y; Qian M; Cao J; Shuai W; Jiao Z
Int J Antimicrob Agents; 2021 Mar; 57(3):106300. PubMed ID: 33567334
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics of vancomycin in extremely obese patients with suspected or confirmed Staphylococcus aureus infections.
Adane ED; Herald M; Koura F
Pharmacotherapy; 2015 Feb; 35(2):127-39. PubMed ID: 25644478
[TBL] [Abstract][Full Text] [Related]
16. Correlation of the vancomycin 24-h area under the concentration-time curve (AUC
Issaranggoon Na Ayuthaya S; Katip W; Oberdorfer P; Lucksiri A
Int J Infect Dis; 2020 Mar; 92():151-159. PubMed ID: 31935538
[TBL] [Abstract][Full Text] [Related]
17. Optimizing Vancomycin Use Through 2-Point AUC-Based Therapeutic Drug Monitoring in Pediatric Patients.
Suchartlikitwong P; Anugulruengkitt S; Wacharachaisurapol N; Jantarabenjakul W; Sophonphan J; Theerawit T; Chatsuwan T; Wattanavijitkul T; Puthanakit T
J Clin Pharmacol; 2019 Dec; 59(12):1597-1605. PubMed ID: 31342543
[TBL] [Abstract][Full Text] [Related]
18. A stewardship program's retrospective evaluation of vancomycin AUC24/MIC and time to microbiological clearance in patients with methicillin-resistant Staphylococcus aureus bacteremia and osteomyelitis.
Gawronski KM; Goff DA; Brown J; Khadem TM; Bauer KA
Clin Ther; 2013 Jun; 35(6):772-9. PubMed ID: 23795575
[TBL] [Abstract][Full Text] [Related]
19. Association between vancomycin trough concentration and area under the concentration-time curve in neonates.
Frymoyer A; Hersh AL; El-Komy MH; Gaskari S; Su F; Drover DR; Van Meurs K
Antimicrob Agents Chemother; 2014 Nov; 58(11):6454-61. PubMed ID: 25136027
[TBL] [Abstract][Full Text] [Related]
20. Evaluating the Relationship between Vancomycin Trough Concentration and 24-Hour Area under the Concentration-Time Curve in Neonates.
Tseng SH; Lim CP; Chen Q; Tang CC; Kong ST; Ho PC
Antimicrob Agents Chemother; 2018 Apr; 62(4):. PubMed ID: 29358290
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
